Invesco RSPH and iShares IBB offer distinct healthcare ETF strategies

Invesco S&P 500 Equal Weight Health Care ETF (RSPH) and iShares Biotechnology ETF (IBB) present contrasting approaches to healthcare exposure, with RSPH providing a broader, equal-weighted portfolio and IBB delivering concentrated, market-cap-weighted biotechnology holdings. The two funds differ significantly in their underlying composition, expense ratios, and payout structures, catering to different risk appetites among investors.

RSPH holds 61 positions with 100% exposure to the healthcare sector. Its top holdings include Moderna (MRNA) at 2.70%, Illumina (ILMN) at 2.02%, and Mettler-Toledo International (MTD) at 1.97%. Launched in 2006, the fund carries an expense ratio of 0.4% and has paid $0.22 per share over the trailing 12 months. Based on a recent share price of approximately $39.1, this translates to a dividend yield of 0.6%. The equal-weighting methodology is designed to mitigate concentration risk, preventing any single company from disproportionately affecting fund performance.

In contrast, IBB is more specialized, allocating 87% of its assets to biotechnology, 9% to life sciences tools and services, and 3% to pharmaceuticals. The fund holds 243 positions, with its largest stakes in Gilead Sciences (GILD) at 8.66%, Amgen (AMGN) at 8.12%, and Vertex Pharmaceuticals (VRTX) at 7.52%. Launched in 2001, IBB has a slightly higher expense ratio of 0.44%. It has distributed $0.34 per share over the trailing 12 months, which works out to a yield of 0.2% on a recent share price of about $207.4.

The performance context for both funds has been favorable over the past year, driven by pharmaceutical dealmaking, enthusiasm for GLP-1 drugs, and a busy FDA approval calendar. RSPH offers a yield gap of 0.41 percentage points compared to IBB and is considered a more dependable choice for long-term investors seeking stability. IBB appeals to those with higher risk tolerance who believe biotechnology momentum will continue, though its concentrated nature means it can experience sharp moves in either direction based on news cycles.

Beta for these funds is calculated from monthly returns over the available history, up to five years, measuring volatility relative to the S&P 500. While fees are nearly identical, the structural differences between the broad healthcare focus of RSPH and the niche biotechnology focus of IBB remain the primary drivers for investor selection.